{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:02:46Z","timestamp":1774645366881,"version":"3.50.1"},"reference-count":48,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk &amp; Safety in Medicine"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The safety of medicines is a critical public health concern that requires continuous monitoring and evaluation throughout a drug\u2019s lifecycle, including post-authorization. Over the past decade, Portugal has undergone significant changes in its pharmaceutical sector, driven by regulatory actions from the National Authority of Medicines and Health Products (INFARMED, I.P.), which ensures the safety, effectiveness, and quality of medicines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aimed to analyze the regulatory actions taken due to safety concerns in Portugal from 2013 to 2023.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective analysis was conducted using safety alerts published by INFARMED, I.P. between January 2013 and December 2023. The analysis focused on changes in marketing status, drugs involved, causes of regulatory actions, and yearly patterns.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>During the study period, 602 safety and quality alerts were issued, being 41 from safety and 561 from quality. The highest number of regulatory actions occurred in 2018, with 172 cases (28.57%). Generic drugs accounted for the majority, with 432 cases (72.19%). Batch recalls (76.65%) corresponded to the main regulatory action related to quality. Quality alerts were often related to impurities or stability (65.42%), non-conformity with GMP standards (11.76%), and labeling or packaging problems (10.70%). Unfavorable risk-benefit ratios were the cause of 100% of safety-related alerts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The findings highlight the importance of robust surveillance systems and continuous evaluation of manufacturing and regulatory processes to enhance drug safety. Collaboration between regulators, the pharmaceutical industry, and healthcare professionals is essential to ensure that the benefits of medicines consistently outweigh the risks associated with their use.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1177\/09246479241301250","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T04:20:46Z","timestamp":1742012446000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-marketing regulatory actions in Portugal\u2014A retrospective analysis between 2013 and 2023"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9402-0341","authenticated-orcid":false,"given":"V\u00edtor","family":"Silva","sequence":"first","affiliation":[{"name":"Unidade Local de Sa\u00fade de Coimbra, EPE, Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-0062","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Joaquim","sequence":"additional","affiliation":[{"name":"Instituto Polit\u00e9cnico de Coimbra, ESTESC-Coimbra Health School, Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6279-1421","authenticated-orcid":false,"given":"Cristiano","family":"Matos","sequence":"additional","affiliation":[{"name":"Instituto Polit\u00e9cnico de Coimbra, ESTESC-Coimbra Health School, Coimbra, Portugal"},{"name":"QLV Research Consulting, Coimbra, Portugal"}]}],"member":"179","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"1","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature","volume":"14","author":"Onakpoya IJ","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med 2016; 14: 1.","journal-title":"BMC Med"},{"key":"e_1_3_3_3_2","article-title":"From laboratory to patient\u2014the journey of a medicine assessed by EMA","author":"European Medicines Agency","year":"2019","unstructured":"European Medicines Agency. From laboratory to patient\u2014the journey of a medicine assessed by EMA. European Medicines agency 2019. https:\/\/www.ema.europa.eu\/en\/documents\/other\/laboratory-patient-journey-centrally-authorised-medicine_en.pdf.","journal-title":"European Medicines agency"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.05.011"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620938595"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/27550834221141767"},{"key":"e_1_3_3_7_2","article-title":"The importance of pharmacovigilance","author":"World Health Organization","year":"2002","unstructured":"World Health Organization. The importance of pharmacovigilance. World Health Organization 2002. https:\/\/iris.who.int\/bitstream\/handle\/10665\/42493\/a75646.pdf.","journal-title":"World Health Organization"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1577818"},{"issue":"6","key":"e_1_3_3_9_2","first-page":"1342","article-title":"A pharmaceutical manufacturer\u2019s perspective on reporting adverse drug experiences","volume":"47","author":"Sullivan JW","year":"1990","unstructured":"Sullivan JW. A pharmaceutical manufacturer\u2019s perspective on reporting adverse drug experiences. Am J Hosp Pharm 1990; 47(6): 1342\u20131345.","journal-title":"Am J Hosp Pharm"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1090707"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01720610-201111000-00001"},{"key":"e_1_3_3_12_2","unstructured":"European Medicines Agency. Notifying a change to the marketing status. 2024. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/notifying-change-marketing-status"},{"key":"e_1_3_3_13_2","volume-title":"CIOMS cumulative glossary","author":"Council for International Organizations of Medical Sciences (CIOMS)","year":"2024","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). CIOMS cumulative glossary. Anniversary ed. Geneva: CIOMS; 2024. https:\/\/cioms.ch\/publications\/product\/cioms-cumulative-glossary-anniversary-edition\/"},{"key":"e_1_3_3_14_2","article-title":"Pharmacovigilance: ensuring the safe use of medicines","author":"World Health Organization","year":"2004","unstructured":"World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. WHO Policy Perspectives on Medicines 2004. https:\/\/iris.who.int\/bitstream\/handle\/10665\/68782\/WHO_EDM_2004.8.pdf.","journal-title":"WHO Policy Perspectives on Medicines"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.4103\/0975-7406.154424"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2005.02.037"},{"key":"e_1_3_3_17_2","first-page":"1","volume-title":"The importance of pharmacovigilance: safety monitoring of medicinal products","author":"World Health Organization","year":"2002","unstructured":"World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO, 2002, pp. 1\u201348."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/1741134320953875"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629040-00004"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528090-00007"},{"key":"e_1_3_3_21_2","first-page":"428","article-title":"Attitudes of community pharmacy professionals towards consumers reporting in Portugal","volume":"25","author":"Matos C","year":"2016","unstructured":"Matos C, Rodrigues L, Joaquim J, et al. Attitudes of community pharmacy professionals towards consumers reporting in Portugal. Pharmacoepidemiol Drug Saf 2016; 25: 428\u2013429.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1867-2"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620953935"},{"issue":"1","key":"e_1_3_3_24_2","first-page":"19","article-title":"Farmacovigil\u00e2ncia--A caminho do Futuro","volume":"15","author":"Advinha AM","year":"2023","unstructured":"Advinha AM. Farmacovigil\u00e2ncia--A caminho do Futuro. Rev Port Farmac 2023; 15(1\u20132): 19\u201322.","journal-title":"Rev Port Farmac"},{"key":"e_1_3_3_25_2","volume-title":"National authority of medicines and health products I.P. (Autoridade Nacional do Medicamento e Produtos de Sa\u00fade, I.P.)","author":"INFARMED","year":"2023","unstructured":"INFARMED. National authority of medicines and health products I.P. (Autoridade Nacional do Medicamento e Produtos de Sa\u00fade, I.P.). Lisbon: INFARMED, 2023. https:\/\/www.infarmed.pt\/web\/infarmed\/circulares"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2020.06.064"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013509233"},{"key":"e_1_3_3_28_2","unstructured":"European Medicines Agency. Paracetamol modified-release - referral. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/paracetamol-modified-release"},{"key":"e_1_3_3_29_2","unstructured":"European Medicines Agency. Fosfomycin-containing medicinal products - referral. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/fosfomycin-containing-medicinal-products"},{"key":"e_1_3_3_30_2","unstructured":"European Medicines Agency. Volume 9A of the rules governing medicinal products in the European union. 2008. https:\/\/ec.europa.eu\/docsroom\/documents\/2809\/attachments\/1\/translations\/en\/renditions\/pdf"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/11597850-000000000-00000"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2017.02.005"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0057-3"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199609147.001.0001"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-00422"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.2174\/1574886314666191004092520"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1670-5"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.07.015"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1090707"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.04.007"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.03.006"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24203804"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.52711\/0975-4377.2021.00052"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.05.022"},{"key":"e_1_3_3_45_2","volume-title":"Proceedings of the international conference on industrial engineering and operations management, Rome, Italy, July 26-28, 2022","author":"Silva A","year":"2022","unstructured":"Silva A, Sousa J, Marques C. Supply chain resiliency in the pharmaceutical industry \u2013 a simulation-based approach. Proceedings of the international conference on industrial engineering and operations management, Rome, Italy, July 26-28, 2022. IEOM Society International, 2022."},{"key":"e_1_3_3_46_2","volume-title":"Circular Informativa N.\u00b0 101\/CD\/8.1.7: Recolha de lotes dos medicamentos Aceclofenac Germed e Aceclofenac Mylan","author":"INFARMED","year":"2013","unstructured":"INFARMED. Circular Informativa N.\u00b0 101\/CD\/8.1.7: Recolha de lotes dos medicamentos Aceclofenac Germed e Aceclofenac Mylan. Lisboa: INFARMED - Autoridade Nacional do Medicamento e Produtos de Sa\u00fade, I.P, 2013."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408444.2016.1149452"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/1741134319859394"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2016-000122"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479241301250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09246479241301250","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479241301250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:21:47Z","timestamp":1750533707000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09246479241301250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/09246479241301250"],"URL":"https:\/\/doi.org\/10.1177\/09246479241301250","relation":{},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}